Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2013

View Archived Issues

Biomarker analysis and mental fitness testing for driving aptitude in patients with cirrhosis

Gilead Sciences reviews events of second quarter 2013

Targeting Abeta oligomers for the treatment of Alzheimer's disease

Bayer discloses novel sGC activators for cardiovascular disorders

Baltic Bio synthesizes new AMPK activators for diabetes

Cellmid collaborates on marker for colorectal cancer diagnosis

Preclinical and clinical evaluation of a snake venom polypeptide as an antithrombotic

Ex vivo evaluation of a bispecific antibody for the treatment of patients with hemophilia A

Phase II study of SHACT meets efficacy and safety endpoints

Signature Therapeutics receives award to advance abuse-deterrent oxycodone

Nektar Therapeutics completes enrollment in phase III BEACON study

ReGenX Biosciences and Audentes Therapeutics to develop NAV vector treatments

Summit awarded grant to develop DMD therapy

Spanish researchers discover biomarker for Lewy body dementia diagnosis

Omeros submits NDA to the FDA for OMS-302

IntelligentMDx receives FDA clearance for vancomycin-resistant enterococci assay

BioDelivery Sciences submits NDA to FDA for Bunavail

PrEP trial to evaluate prevention using antiretroviral drugs in HIV-negative individuals

S1 Biopharma initiates phase IIa trial of Lorexys in premenopausal women with HSDD

New company AveXis to focus on new technology for disease treatment

OncoTherapy Science identifies potent drug candidates for a novel kinase target

Cubist Pharmaceuticals signs agreements to acquire two companies

OncoTherapy's phase III trial of peptide cocktail vaccine for pancreatic cancer remains on schedule

MolecularMD obtains license for cancer diagnosis technology

Takeda receives marketing authorization in China for Nesina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...